Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mounjaro in obstructive sleep apnea with obesity (China phase 3)
CTR20222427Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, sponsored by Eli Lilly and Company. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20222427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222427.